The company have significantly improved the development of the new treatment for ATTR-CM, leveraging Attruby. Initial clinical data indicates potential outcomes for patients diagnosed with this serious condition. The https://biotech220793.vidublog.com/40761365/firm-improves-cardiac-amyloidosis-treatment-with-the-therapy